Healthcare provider profile · identity verified

Mark Lee Ginnings, M.D.

Internal Medicine · DENTON, TX · NPI 1205830643

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	438	112
Losartan Potassium	Losartan Potassium	390	103
Atorvastatin Calcium	Atorvastatin Calcium	377	111
Rosuvastatin Calcium	Rosuvastatin Calcium	318	103
Amlodipine Besylate	Amlodipine Besylate	313	91
Lisinopril	Lisinopril	275	85
Omeprazole	Omeprazole	174	48
Metoprolol Succinate	Metoprolol Succinate	171	53
Metformin Hcl	Metformin Hcl	167	53
Hydrochlorothiazide	Hydrochlorothiazide	163	47
Pantoprazole Sodium	Pantoprazole Sodium	163	46
Tamsulosin Hcl	Tamsulosin Hcl	150	44
Pravastatin Sodium	Pravastatin Sodium	136	36
Gabapentin	Gabapentin	132	42
Simvastatin	Simvastatin	121	39
Allopurinol	Allopurinol	118	30
Ozempic	Semaglutide	109	21
Sertraline Hcl	Sertraline Hcl	106	24
Potassium Chloride	Potassium Chloride	105	25
Trazodone Hcl	Trazodone Hcl	93	19
Fluticasone Propionate	Fluticasone Propionate	92	38
Montelukast Sodium	Montelukast Sodium	90	27
Synthroid	Levothyroxine Sodium	90	27
Duloxetine Hcl	Duloxetine Hcl	82	24
Eliquis	Apixaban	78	16
Escitalopram Oxalate	Escitalopram Oxalate	77	20
Furosemide	Furosemide	72	29
Carvedilol	Carvedilol	71	19
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	71	22
Metformin Hcl Er	Metformin Hcl	68	21
Metoprolol Tartrate	Metoprolol Tartrate	64	15
Finasteride	Finasteride	62	16
Glimepiride	Glimepiride	61	16
Glipizide Er	Glipizide	61	22
Spironolactone	Spironolactone	59	16
Famotidine	Famotidine	58	16
Clopidogrel	Clopidogrel Bisulfate	57	16
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	57	15
Tramadol Hcl	Tramadol Hcl	56	11
Alendronate Sodium	Alendronate Sodium	54	16
Atenolol	Atenolol	54	14
Nifedipine Er	Nifedipine	49	12
Ezetimibe	Ezetimibe	43	13
Lovastatin	Lovastatin	42	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	39	16
Donepezil Hcl	Donepezil Hcl	39	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	38	suppressed
Indapamide	Indapamide	37	12
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	34	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	34	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	28	suppressed
Jardiance	Empagliflozin	27	12
Colchicine	Colchicine	26	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	26	suppressed
Mounjaro	Tirzepatide	26	suppressed
Glipizide	Glipizide	25	suppressed
Memantine Hcl	Memantine Hcl	25	suppressed
Warfarin Sodium	Warfarin Sodium	25	suppressed
Alprazolam	Alprazolam	24	suppressed
Azelastine Hcl	Azelastine Hcl	24	suppressed
Buspirone Hcl	Buspirone Hcl	24	suppressed
Januvia	Sitagliptin Phosphate	23	suppressed
Meloxicam	Meloxicam	23	suppressed
Mirtazapine	Mirtazapine	23	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	23	suppressed
Pregabalin	Pregabalin	23	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	22	suppressed
Farxiga	Dapagliflozin Propanediol	22	suppressed
Bupropion Xl	Bupropion Hcl	21	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	21	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	20	suppressed
Ropinirole Hcl	Ropinirole Hcl	20	suppressed
Tizanidine Hcl	Tizanidine Hcl	20	15
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	18	17
Celecoxib	Celecoxib	18	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	18	suppressed
Myrbetriq	Mirabegron	18	suppressed
Nitroglycerin	Nitroglycerin	18	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	18	18
Ramipril	Ramipril	18	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	17	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	16	suppressed
Chlorthalidone	Chlorthalidone	16	suppressed
Citalopram Hbr	Citalopram Hydrobromide	16	suppressed
Estradiol	Estradiol	16	suppressed
Hydralazine Hcl	Hydralazine Hcl	16	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	16	suppressed
Valsartan	Valsartan	16	suppressed
Fenofibrate	Fenofibrate	15	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	15	suppressed
Sucralfate	Sucralfate	15	suppressed
Dutasteride	Dutasteride	14	suppressed
Ipratropium Bromide	Ipratropium Bromide	14	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	14	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	14	suppressed
Xarelto	Rivaroxaban	14	suppressed
Amoxicillin	Amoxicillin	13	12
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	13	suppressed
Methylprednisolone	Methylprednisolone	13	13
Acebutolol Hcl	Acebutolol Hcl	12	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	12	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	12	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	12	suppressed
Memantine Hcl Er	Memantine Hcl	12	suppressed
Midodrine Hcl	Midodrine Hcl	12	suppressed
Nebivolol Hcl	Nebivolol Hcl	12	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	12	11
Valproic Acid	Valproic Acid	12	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	11	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	11	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	11	suppressed
Primidone	Primidone	11	suppressed
Tramadol Hcl-Acetaminophen	Tramadol Hcl/Acetaminophen	11	suppressed
Trulicity	Dulaglutide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error